Stock Market Update - October 15, 2026
Today's stock market saw some significant movers. Here's a breakdown of 5 stocks that caught our attention:
1. ESLA - Estrella Immunopharma, Inc.
Price: $0.5352 | Change: +68.35% ($0.2173)
ESLA saw its shares rocket by an impressive 68.35% following a major announcement from Estrella Immunopharma, Inc. The company revealed highly encouraging results from the STARLIGHT-1 Phase I clinical trial for its investigational T-cell therapy, EB103, designed to treat a serious form of lymphoma.
The primary driver was the reported "excellent tolerability and a 100% complete response rate" in the high-dose group during the trial's early phase. This means the therapy was well-tolerated by patients, and every patient in that specific group saw their cancer fully disappear. Further positive data showed patients continued to tolerate the treatment well, with no serious side effects reported.
What made these results particularly impactful was the indication of potential durability; some patients who achieved a complete response remained disease-free for nine months. This early success significantly bolstered investor confidence in Estrella's proprietary ARTEMIS T-cell therapy platform.
2. XLAB - Exascale Labs Holdings Inc.
Price: $1.36 | Change: +49.70% ($0.4515)
XLAB just soared an impressive 49.70% around October 16, 2026, driven primarily by the announcement of a major partnership. Exascale Labs secured an $8.21 million deal with Sunon Inc., disclosed via an 8-K filing on October 15. Under the agreement, Exascale will provide 12 NVIDIA HGX B300 GPU servers, along with essential network equipment, deployment services, and three years of comprehensive IT operation services.
This substantial contract is set to establish a defined revenue stream and generate recurring income for Exascale Labs over a three-year period. Adding to the positive market sentiment are the company's strong fiscal year 2026 financial results, which reported a significant 111% revenue growth to $14.8 million, and its recent successful Nasdaq listing in late August 2026.
What makes this particularly interesting is how this partnership validates the demand for Exascale's specialized deployment and managed services model, built upon cutting-edge NVIDIA-class AI infrastructure. This shows the company's ability to capitalize on the growing need for powerful AI computing solutions.
3. WETO - Wetour Robotics Limited
Price: $1.22 | Change: +46.88% ($0.3894)
WETO experienced an impressive 46.88% jump recently, following a strategic announcement from Wetour Robotics Limited. The company decided to voluntarily hit pause on selling new shares through its "at-the-market" (ATM) equity offering program.
This was a crucial catalyst because ATM programs allow companies to sell new shares directly into the market, which can dilute the value of existing shareholder holdings. By pausing this, Wetour Robotics, a company focusing on Physical AI infrastructure and wearable robotics, effectively eased immediate concerns about potential dilution among its investors.
The market reacted favorably to this strategic financial decision, highlighting how investors often prioritize the protection of their current share value. While the ATM agreement technically remains in place for potential future use, this temporary halt was enough to spark significant positive sentiment.
4. DRMA - Dermata Therapeutics, Inc.
Price: $0.91 | Change: +37.19% ($0.2467)
DRMA experienced a significant 37.19% surge, thanks to some exciting news in the world of dermatologic solutions. Dermata Therapeutics announced positive topline results from a cosmetic clinical study for its recently launched product, Tome Foundational Treatment.
The study highlighted compelling efficacy and high participant satisfaction. A remarkable 93% of participants felt the treatment was comparable to a professional in-office procedure, and 90% reported more noticeable results than other products, improving areas like fine lines and overall appearance without any reported adverse events.
This positive data, coming right after the commercial launch of Tome Foundational Treatment, has clearly boosted investor confidence. With the product already available for purchase online, these favorable findings provide a strong catalyst for its market presence.
5. SVRE - SaverOne 2014 Ltd
Price: $1.65 | Change: +35.25% ($0.43)
SVRE just posted a significant 35.25% gain. This upward movement, noted since early October 2026, was largely fueled by a key U.S. patent win on September 29, 2026. The patent, for "Automated Sensor Fusion Calibration and Maintenance," significantly boosts SaverOne's intellectual property for its transportation safety solutions, particularly important for preventing distracted driving in fleet deployments.
Beyond this IP win, investors are optimistic about SaverOne's strategic pivot into higher-value defense and security markets. Earlier in 2026, the company entered the military UAV market by agreeing to acquire a stake in Gryphen Aircraft Industries and deepened its collaboration with VisionWave on an RF Defense Platform. These initiatives highlight SaverOne's efforts to broaden its RF sensing technology applications, and the market is clearly reacting positively to these diversified strategic moves.
This analysis was generated using AI and real-time stock data. Always do your own research before making investment decisions.